Antibody Drug Dispute Ends in $255 Million Cash Payout
E. Kintisch
DOI: https://doi.org/10.1126/SCIENCE.310.5749.761A
IF: 56.9
2005-11-04
Science
Abstract:Developers of a new drug for arthritis last week ended a 2-year dispute over royalties, leading to one of the biggest-ever lump-sum payments on record to academic scientists. The payoff came after a U.K. biotech firm, Cambridge Antibody Technology (CAT), withdrew a suit against its giant partner Abbott in Abbott Park, Illinois.
The settlement between CAT and Abbott will release a total of $255 million in royalties, to be split between the U.S. nonprofit Scripps Research Institute, the U.S. biotech firm Stratagene, and the U.K. Medical Research Council (MRC), which helped fund early studies. The deal cuts future royalties Abbott must pay on Humira, a blockbuster anti-inflammatory drug made with a process patented by Scripps and MRC scientists.
“I expect it will be one of the single largest academic licensing transactions in the United Kingdom's history and would be very high on the list of North American licensing transactions,” says Ashley Stevens, technology transfer director at Boston University. Emory University in Atlanta, Georgia, holds the record, though: In July, it sold the rights to AIDS drug Emtriva for a one-time payment of $525 million. U.S. universities in 2003 garnered $1.3 billion in licensing revenue from science discoveries, according to the Association of University Technology Managers.
At the heart of the CAT-Abbott deal is a technique to create human antibodies to order. Previously, animal cells were used to derive antibodies for medical therapies, and as a result, candidate drugs triggered an immune attack by the patients' own cells. Competing labs at MRC and Scripps published landmark papers on techniques to derive human monoclonal antibodies in 1989 ( Science , 8 December 1989, p. 1275; Nature , 12 October 1989, p. 544). Nine years later, after shelving a patent dispute, the teams joined forces under the auspices of CAT. Abbott and CAT then partnered to produce Humira but eventually found themselves at odds in 2003 over profits; Abbott attempted to reduce the royalty rate to the inventors, citing contract provisions, and CAT sued. The parties settled out of court last week.
Doctors have prescribed Humira to more than 110,000 patients worldwide for rheumatoid arthritis. In addition, drugs based on the MRC-Scripps antibody technique are in clinical trials for Crohn's disease and ankylosing spondylitis.
“You like to see academic research ultimately go to products to help people,” says chemist Richard Lerner, a co-inventor and now president of Scripps. “Humira is a very good product,” adds co-inventor Gregory Winter, an MRC researcher at the University of Cambridge, U.K., in part because it is formulated in a way that permits patients to administer injections themselves. “I think [analysts] believe the market will go to about $1.6 billion.”
MRC and Scripps are poised to receive $191 million and $34 million respectively, with roughly $45 million more in the offing. Lerner is entitled to a quarter of Scripps's take; the U.K. inventors to 10%-15% of MRC's share. None has decided how the money will be used. San Diego, California-based Stratagene will receive $24 million for related patents.